These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 34059612)
1. Update on cardiovascular risk in nonalcoholic fatty liver disease. Johnston MP; Patel J; Byrne CD Curr Opin Cardiol; 2021 Jul; 36(4):478-486. PubMed ID: 34059612 [TBL] [Abstract][Full Text] [Related]
2. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Caussy C; Aubin A; Loomba R Curr Diab Rep; 2021 Mar; 21(5):15. PubMed ID: 33742318 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558 [TBL] [Abstract][Full Text] [Related]
4. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
5. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019 [TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Chiriac S; Stanciu C; Girleanu I; Cojocariu C; Sfarti C; Singeap AM; Cuciureanu T; Huiban L; Muzica CM; Zenovia S; Nastasa R; Trifan A Can J Gastroenterol Hepatol; 2021; 2021():6696857. PubMed ID: 33505944 [TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Cai J; Zhang XJ; Ji YX; Zhang P; She ZG; Li H Circ Res; 2020 Feb; 126(5):679-704. PubMed ID: 32105577 [TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Byrne CD; Targher G Diabetes Obes Metab; 2022 Feb; 24 Suppl 2():28-43. PubMed ID: 34324263 [TBL] [Abstract][Full Text] [Related]
13. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Budd J; Cusi K Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726 [TBL] [Abstract][Full Text] [Related]
14. NAFLD and cardiovascular diseases: a clinical review. Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080 [TBL] [Abstract][Full Text] [Related]